ImmunityBio announced that the FDA has approved Anktiva plus Bacillus Calmette-Guerin, or BCG, for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer, or NMIBC, with carcinoma in situ, or CIS, with or without papillary tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX: